{ "schemaVersion": 1, "organisationId": "O-6df5756b50864831aa9d837cb79ca83d", "slug": "icon-plc", "name": "ICON PLC", "updatedAt": "2026-10-02T12:42:50.453995Z", "sections": [ { "type": "OVERVIEW", "text": "ICON plc is a global contract research organization (CRO) serving pharmaceutical, biotechnology, medical-device, government and public-health organizations. Its services span clinical development—from early-stage studies through Phase I–IV trials—to post-approval research, commercialization, market access consulting and healthcare technology. [P153819551][P153819552] The company’s stated mission is to improve patients’ lives by accelerating the development of customers’ drugs and devices through innovative solutions. [P153819618]\n\nFounded in Dublin in 1990, ICON operates internationally; as of September 30, 2025, it reported approximately 39,800 employees, 106 locations in 55 countries, and service-delivery capability in 93 countries. [https://www.iconplc.com/about][https://www.iconplc.com/news-events/mediakit/facts-and-figures] For the year ended December 31, 2025, revenue was approximately $8.251 billion. [https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and]\n[P153819551][P153819552][P153819618][https://www.iconplc.com/about][https://www.iconplc.com/news-events/mediakit/facts-and-figures][https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and][https://www.iconplc.com/about][https://www.iconplc.com/news-events/mediakit/facts-and-figures][https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and]", "updatedAt": "2026-10-02T12:42:50.453995Z" }, { "type": "PRODUCTS", "text": "ICON provides clinical development services spanning Phases I–IV, peri- and post-approval studies, trial design and execution, data solutions, consulting, contract staffing and commercialization support. Its laboratory services include central, bioanalytical, biomarker, vaccine, GMP and specialty testing; work can be delivered as full-service programs, strategic partnerships, functional service provision or stand-alone services. [P153819454][P153819498][P153819500][https://www.iconplc.com/solutions/laboratories/global-central-laboratories]\n\nNamed technology offerings support different stages of trial operations. ICON Digital Platform includes eConsent, electronic clinical outcome assessments (eCOA), eSource, televisits and connected-device data capture. FIRECREST provides site-facing tools for communications, training, document exchange, pre-screening, eConsent and safety-letter workflows, while HORIZON tracks site-activation milestones and offers dashboards, predictive analytics and workflow automation. Other tools described by ICON include One Search for AI/ML-assisted site selection, SmartDraft for contract drafting, Clinical Data Studio for combining data sources, Risk-Based Monitoring for data-led monitoring prioritization, and Flex Advantage for randomization and trial-supply management. [P153819805][P153819812][P153819817][P153819820][P153819821][https://www.iconplc.com/solutions/technologies/icon-digital-platform][https://www.iconplc.com/solutions/technologies/firecrest][https://www.iconplc.com/solutions/technologies/horizon]\n\nAccellacare offers site and patient services, including site start-up, recruitment and retention support, site resourcing, and in-home trial visits. ICON’s filing describes its owned or embedded site network and in-home services; company pages also describe central-lab sample tracking and kit management through LabView360. ICON reports one reportable segment and does not disclose revenue or performance percentages by individual product or service. [P153819514][P153819515][P153819517][P153822118][https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions][https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services][https://www.iconplc.com/solutions/technologies/labview360]\n[P153819454][P153819498][P153819500][https://www.iconplc.com/solutions/laboratories/global-central-laboratories][P153819805][P153819812][P153819817][P153819820][P153819821][https://www.iconplc.com/solutions/technologies/icon-digital-platform][https://www.iconplc.com/solutions/technologies/firecrest][https://www.iconplc.com/solutions/technologies/horizon][P153819514][P153819515][P153819517][P153822118][https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions][https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services][https://www.iconplc.com/solutions/technologies/labview360][https://www.iconplc.com/solutions/laboratories/global-central-laboratories][https://www.iconplc.com/solutions/technologies/icon-digital-platform][https://www.iconplc.com/solutions/technologies/firecrest][https://www.iconplc.com/solutions/technologies/horizon][https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions][https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services][https://www.iconplc.com/solutions/technologies/labview360]", "updatedAt": "2026-10-02T12:42:50.453995Z" }, { "type": "GEOGRAPHY", "text": "In FY2025, ICON plc reported revenue of 30.6% from the United States, 57.9% from Europe, and 11.5% from the Rest of the World. Its geographic revenue discussion separately reported $3,183.6 million in Ireland, $1,590.9 million in the rest of Europe, $2,524.9 million in the United States, and $951.9 million in the Rest of the World/Other. ICON cautions that Ireland revenue primarily reflects its global contracting model, rather than necessarily indicating where customers are located or services are performed. [P153819901][P153819902][P153819903]\n\nAt December 31, 2025, ICON had approximately 40,100 employees at 97 locations in 55 countries; the filing does not give an employee breakdown by region. [P153819883] Its corporate headquarters are in Leopardstown, Dublin, Ireland. [https://www.iconplc.com/contact]\n[P153819901][P153819902][P153819903][P153819883][https://www.iconplc.com/contact]", "updatedAt": "2026-10-02T12:42:50.453995Z" }, { "type": "SEGMENTS", "text": "ICON reports one financial segment: the global provision of outsourced development services to pharmaceutical, biotechnology and medical-device companies. This segment represents 100% of reported revenue; FY2025 revenue was $8.251 billion. ICON does not report revenue contributions separately for its service lines. [P153822118][P153822120][https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and]\n\nIts service offerings include early-phase development and clinical pharmacology; clinical-trial operations and data science; site and patient support, including recruitment and retention; laboratory testing; and consulting on development, regulatory strategy and commercial positioning. These are service categories, not separately reported financial segments, so no revenue percentages can be assigned to them from ICON’s disclosures. [https://www.iconplc.com/solutions/early-clinical][https://www.iconplc.com/solutions/clinical-scientific-operations][https://www.iconplc.com/solutions/site-and-patient-solutions][https://www.iconplc.com/solutions/laboratories][https://www.iconplc.com/solutions/consulting][https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting]\n[P153822118][P153822120][https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and][https://www.iconplc.com/solutions/early-clinical][https://www.iconplc.com/solutions/clinical-scientific-operations][https://www.iconplc.com/solutions/site-and-patient-solutions][https://www.iconplc.com/solutions/laboratories][https://www.iconplc.com/solutions/consulting][https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting][https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and][https://www.iconplc.com/solutions/early-clinical][https://www.iconplc.com/solutions/clinical-scientific-operations][https://www.iconplc.com/solutions/site-and-patient-solutions][https://www.iconplc.com/solutions/laboratories][https://www.iconplc.com/solutions/consulting][https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting]", "updatedAt": "2026-10-02T12:42:50.453995Z" }, { "type": "HISTORY", "text": "ICON plc was founded in Dublin in 1990 by Dr. John Climax and Dr. Ronan Lambe, initially with a five-person team. It completed its initial public offering on May 15, 1998. [P153819452][https://www.iconplc.com/about/company-history][https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3][https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4]\n\nDuring the 2000s and 2010s, ICON expanded its geographic reach and broadened its services through acquisitions, including UK regulatory-affairs consultancy YRCR and US clinical-trial laboratory UCT in 2000, clinical-development company Aptiv Solutions in 2014, and health-outcomes research firm Mapi Group in 2017. [https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71][https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory][https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions][https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group]\n\nIn 2021, ICON completed its acquisition of PRA Health Sciences, creating a larger clinical research organization under the ICON name. It acquired KCR in 2024. In 2025, Barry Balfe succeeded Steve Cutler as CEO, marking a leadership transition after Cutler had led the company since 2017. [P153819471][https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation][https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm][P153820209][https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition]\n[P153819452][https://www.iconplc.com/about/company-history][https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3][https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4][https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71][https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory][https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions][https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group][P153819471][https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation][https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm][P153820209][https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition][https://www.iconplc.com/about/company-history][https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3][https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4][https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71][https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory][https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions][https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group][https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation][https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm][https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition]", "updatedAt": "2026-10-02T12:42:50.453995Z" } ], "sources": [ { "id": "P153819551", "href": "https://app.finbar.com/go?id=P153819551", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819552", "href": "https://app.finbar.com/go?id=P153819552", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819618", "href": "https://app.finbar.com/go?id=P153819618", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/about", "href": "https://www.iconplc.com/about", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/news-events/mediakit/facts-and-figures", "href": "https://www.iconplc.com/news-events/mediakit/facts-and-figures", "label": "www.iconplc.com" }, { "id": "https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and", "href": "https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and", "label": "investor.iconplc.com" }, { "id": "P153819454", "href": "https://app.finbar.com/go?id=P153819454", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819498", "href": "https://app.finbar.com/go?id=P153819498", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819500", "href": "https://app.finbar.com/go?id=P153819500", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/solutions/laboratories/global-central-laboratories", "href": "https://www.iconplc.com/solutions/laboratories/global-central-laboratories", "label": "www.iconplc.com" }, { "id": "P153819805", "href": "https://app.finbar.com/go?id=P153819805", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819812", "href": "https://app.finbar.com/go?id=P153819812", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819817", "href": "https://app.finbar.com/go?id=P153819817", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819820", "href": "https://app.finbar.com/go?id=P153819820", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819821", "href": "https://app.finbar.com/go?id=P153819821", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/solutions/technologies/icon-digital-platform", "href": "https://www.iconplc.com/solutions/technologies/icon-digital-platform", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/technologies/firecrest", "href": "https://www.iconplc.com/solutions/technologies/firecrest", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/technologies/horizon", "href": "https://www.iconplc.com/solutions/technologies/horizon", "label": "www.iconplc.com" }, { "id": "P153819514", "href": "https://app.finbar.com/go?id=P153819514", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819515", "href": "https://app.finbar.com/go?id=P153819515", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819517", "href": "https://app.finbar.com/go?id=P153819517", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153822118", "href": "https://app.finbar.com/go?id=P153822118", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions", "href": "https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services", "href": "https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/technologies/labview360", "href": "https://www.iconplc.com/solutions/technologies/labview360", "label": "www.iconplc.com" }, { "id": "P153819901", "href": "https://app.finbar.com/go?id=P153819901", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819902", "href": "https://app.finbar.com/go?id=P153819902", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819903", "href": "https://app.finbar.com/go?id=P153819903", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "P153819883", "href": "https://app.finbar.com/go?id=P153819883", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/contact", "href": "https://www.iconplc.com/contact", "label": "www.iconplc.com" }, { "id": "P153822120", "href": "https://app.finbar.com/go?id=P153822120", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/solutions/early-clinical", "href": "https://www.iconplc.com/solutions/early-clinical", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/clinical-scientific-operations", "href": "https://www.iconplc.com/solutions/clinical-scientific-operations", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/site-and-patient-solutions", "href": "https://www.iconplc.com/solutions/site-and-patient-solutions", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/laboratories", "href": "https://www.iconplc.com/solutions/laboratories", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/consulting", "href": "https://www.iconplc.com/solutions/consulting", "label": "www.iconplc.com" }, { "id": "https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting", "href": "https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting", "label": "www.iconplc.com" }, { "id": "P153819452", "href": "https://app.finbar.com/go?id=P153819452", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/about/company-history", "href": "https://www.iconplc.com/about/company-history", "label": "www.iconplc.com" }, { "id": "https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3", "href": "https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3", "label": "investor.iconplc.com" }, { "id": "https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4", "href": "https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4", "label": "investor.iconplc.com" }, { "id": "https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71", "href": "https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71", "label": "investor.iconplc.com" }, { "id": "https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory", "href": "https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory", "label": "investor.iconplc.com" }, { "id": "https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions", "href": "https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions", "label": "investor.iconplc.com" }, { "id": "https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group", "href": "https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group", "label": "investor.iconplc.com" }, { "id": "P153819471", "href": "https://app.finbar.com/go?id=P153819471", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation", "href": "https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation", "label": "www.iconplc.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm", "href": "https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm", "label": "www.sec.gov" }, { "id": "P153820209", "href": "https://app.finbar.com/go?id=P153820209", "label": "ICON PLC — Full financial report (2025 Y)", "documentId": "D-fffc9223607f474e8d18eeb3aafa0d69" }, { "id": "https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition", "href": "https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition", "label": "www.iconplc.com" } ] }